WithdrawnPHASE2, PHASE3NCT00418431
Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
Studying Central serous chorioretinopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Asociación para Evitar la Ceguera en México
- Principal Investigator
- Mitzy E Torres Soriano, MDAsociación para Evitar la Ceguera en México
- Intervention
- Intravitreal injection of Bevacizumab(drug)
- Eligibility
- 20-50 years · All sexes
- Timeline
- 2006 – 2006
Study locations (1)
- Asociacion para Evitar la Ceguera en Mexico, Mexico City, Mexico City, Mexico
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00418431 on ClinicalTrials.govOther trials for Central serous chorioretinopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06527326the Study of the Association Between the Gut Microbiota and Central Serous ChorioretinopathySecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGNCT06346405Central Serous Chorioretinopathy and Micropulse Laser TreatmentFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNANCT05570591Subthreshold Nanosecond Laser for Non-resolving Central Serous ChorioretinopathyNova Eye Medical Pty Ltd.
- RECRUITINGNCT05589974Choroidal Blood Flow in Acute and Chronic Central Serous ChorioretinopathyHelse Stavanger HF